Diaceutics (LON:DXRX) Trading Down 0.6% - Here's What Happened

Key Points

• Shares fell 0.6% to GBX 164 on Thursday with about 350,458 shares traded, a 154% increase versus the average daily volume.
• Shore Capital raised its target from GBX 180 to GBX 215 and gave a "buy" rating; the consensus from three analysts is a Buy with an average price target of GBX 193.33.
• Key financials: market capitalization £138.79 million, a negative PE of -91.11 and debt-to-equity of 3.05, alongside strong liquidity metrics (current ratio 3.96, quick ratio 9.92).

Diaceutics PLC (LON:DXRX - Get Free Report)'s stock price dropped 0.6% during trading on Thursday . The company traded as low as GBX 164 and last traded at GBX 164. Approximately 350,458 shares were traded during trading, an increase of 154% from the average daily volume of 138,113 shares. The stock had previously closed at GBX 165.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group raised their target price on shares of Diaceutics from GBX 180 to GBX 215 and gave the stock a "buy" rating in a research report on Thursday, January 15th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of GBX 193.33.

Diaceutics Trading Down 0.6%

The firm has a market capitalization of £138.79 million, a PE ratio of -91.11 and a beta of 0.94. The stock's 50-day moving average price is GBX 153.49 and its 200 day moving average price is GBX 153.33. The company has a debt-to-equity ratio of 3.05, a current ratio of 3.96 and a quick ratio of 9.92.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.